Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
Portfolio Pulse from
Invivyd, Inc. announced that The New England Journal of Medicine published a Letter to the Editor on the immunobridging pathway for PEMGARDA™ (pemivibart) leading to its Emergency Use Authorization. The letter also discusses the updated correlate of protection curve for COVID-19 prevention using monoclonal antibodies.
November 14, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's PEMGARDA™ (pemivibart) has been highlighted in a NEJM publication for its emergency use authorization pathway and updated protection curve, potentially boosting its credibility and market interest.
The publication in a prestigious journal like NEJM can enhance the credibility of Invivyd's product, PEMGARDA™, potentially leading to increased investor interest and a positive impact on the stock price. The focus on the EUA pathway and updated protection curve is significant for regulatory and market perspectives.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90